Cite
A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
MLA
Ruiz, Garcia, Ana, et al. “A Phase I Open-Label Study to Investigate the Potential Drug-Drug Interaction between Single-Dose Dacomitinib and Steady-State Paroxetine in Healthy Volunteers.” Journal of Clinical Pharmacology, vol. 54, no. 5, May 2014, pp. 555–62. EBSCOhost, https://doi.org/10.1002/jcph.243.
APA
Ruiz, G. A., Giri, N., LaBadie, R. R., Ni, G., Boutros, T., Richie, N., Kocinsky, H. S., Checchio, T. M., & Bello, C. L. (2014). A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. Journal of Clinical Pharmacology, 54(5), 555–562. https://doi.org/10.1002/jcph.243
Chicago
Ruiz, Garcia, Ana, Nagdeep Giri, Robert R. LaBadie, Grace Ni, Tanya Boutros, Nicole Richie, Hetal S. Kocinsky, Tina M. Checchio, and Carlo L. Bello. 2014. “A Phase I Open-Label Study to Investigate the Potential Drug-Drug Interaction between Single-Dose Dacomitinib and Steady-State Paroxetine in Healthy Volunteers.” Journal of Clinical Pharmacology 54 (5): 555–62. doi:10.1002/jcph.243.